OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+49.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$459M
AUM Growth
+$459M
(+22%)
Cap. Flow
-$115M
Cap. Flow
% of AUM
-25.1%
Top 10 Holdings %
Top 10 Hldgs %
57.01%
Holding
59
New
13
Increased
16
Reduced
16
Closed
7
Top Buys
| 1 |
Lyell Immunopharma
LYEL
|
$7.48M |
| 2 |
Compass Therapeutics
CMPX
|
$6.28M |
| 3 |
Ocular Therapeutix
OCUL
|
$5.31M |
| 4 |
Applied Therapeutics
APLT
|
$4.61M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.29M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$104M |
| 2 |
SLRN
ACELYRIN
SLRN
|
$17.3M |
| 3 |
IDEAYA Biosciences
IDYA
|
$11.1M |
| 4 |
Biohaven
BHVN
|
$8.56M |
| 5 |
Arcutis Biotherapeutics
ARQT
|
$6.33M |
Sector Composition
| 1 | Healthcare | 99.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vaxcyte
PCVX
$4B
| $5.81M | 1.27% | 85,000 -5,000 | -6% | -$342K |
|
|
NYXH
27
Nyxoah
NYXH
$234M
| $4.32M | 0.94% | 320,000 -24,800 | -7% | -$335K |
|
28
Savara
SVRA
$567M
| $4.26M | 0.93% | +855,000 | New | +$4.26M |
|
|
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.21M | 0.92% | 787,545 +428,175 | +119% | +$2.29M |
|
30
UroGen Pharma
URGN
$900M
| $4.05M | 0.88% | 270,000 -50,000 | -16% | -$750K |
|
31
Nurix Therapeutics
NRIX
$714M
| $3.93M | 0.86% | +267,210 | New | +$3.93M |
|
|
RVNC
32
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.86M | 0.84% | +785,000 | New | +$3.86M |
|
33
Relmada Therapeutics
RLMD
$37.2M
| $3.53M | 0.77% | 759,000 -118,000 | -13% | -$549K |
|
34
Protagonist Therapeutics
PTGX
$3.67B
| $3.26M | 0.71% | 112,700 | – | – |
|
35
Zentalis Pharmaceuticals
ZNTL
$122M
| $3.15M | 0.69% | +200,000 | New | +$3.15M |
|
|
ALLK
36
DELISTED
Allakos
ALLK
| $3.07M | 0.67% | +2,435,000 | New | +$3.07M |
|
37
Gossamer Bio
GOSS
$562M
| $2.88M | 0.63% | 2,440,109 -542,091 | -18% | -$640K |
|
38
iBio
IBIO
$16.1M
| $2.76M | 0.6% | +680,000 | New | +$2.76M |
|
39
Verastem
VSTM
$569M
| $2.49M | 0.54% | 211,400 | – | – |
|
40
Aligos Therapeutics
ALGS
$73.3M
| $1.6M | 0.35% | 1,630,000 +333,000 | +26% | +$326K |
|
41
Context Therapeutics
CNTX
$75.4M
| $1.53M | 0.33% | 1,108,357 +133,357 | +14% | +$184K |
|
42
Precigen
PGEN
$1.34B
| $1.37M | 0.3% | 947,500 -65,000 | -6% | -$94.3K |
|
43
Larimar Therapeutics
LRMR
$310M
| $1.32M | 0.29% | 174,413 -449,087 | -72% | -$3.41M |
|
44
Fulcrum Therapeutics
FULC
$351M
| $1.23M | 0.27% | 130,000 | – | – |
|
|
MOR
45
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $1.18M | 0.26% | 65,000 -80,000 | -55% | -$1.45M |
|
46
Glaukos
GKOS
$5.5B
| $809K | 0.18% | +8,576 | New | +$809K |
|
47
PMV Pharmaceuticals
PMVP
$74.2M
| $802K | 0.17% | +471,481 | New | +$802K |
|
48
Biodesix
BDSX
$62.6M
| $765K | 0.17% | 534,657 +38,157 | +8% | +$54.6K |
|
|
RGLS
49
DELISTED
Regulus Therapeutics
RGLS
| $490K | 0.11% | +170,308 | New | +$490K |
|
50
Design Therapeutics
DSGN
$315M
| $456K | 0.1% | +113,038 | New | +$456K |
|